Tag - hepatitis B

Feature

Spring Bank heading into data-rich 2020

Spring Bank Pharmaceuticals (NASDAQ:SBPH) will be reporting clinical data readouts throughout 2020 as it advances a portfolio of three drug candidates for the treatment of chronic hepatitis B virus (HBV) as well as...

November 12, 2019

Markets

Brookline starts Arcturus Therapeutics at buy; PT $25

Brookline Capital Markets launched coverage of Arcturus Therapeutics (NASDAQ:ARCT) with a “buy” rating and price target of $25. The stock closed at $11.80 on July 24. Arcturus is developing RNA-based therapies...

July 25, 2019

Developments

Emerging liver disease company, ContraVir, changes name to Hepion Pharmaceuticals; stock symbol to “HEPA”

ContraVir Pharmaceuticals (NASDAQ:CTRV) announced a name change to Hepion Pharmaceuticals, and a stock symbol change to “HEPA,” effective as of opening of trading on July 23, 2019. “We derived the name “Hepion” by...

July 22, 2019

Feature

Arbutus taking multi-faceted approach to HBV

By Len Zehr Arbutus Biopharma (NASDAQ:ABUS) is developing a portfolio of drug candidates, each with different mechanisms of action that it believes will result in a combination therapy to cure patients infected with...

January 17, 2017

Feature

William Blair analyst discusses Hep B space

By Len Zehr As a partner and biotechnology analyst with William Blair & Co., Y. Katherine Xu was recognized in 2010 by the Financial Times/StarMine “World’s Top Analysts” listing, ranking No. 7 overall for stock...

October 11, 2016

Tag - hepatitis B

Spring Bank heading into data-rich 2020

Brookline starts Arcturus Therapeutics at buy; PT $25

Emerging liver disease company, ContraVir, changes name to Hepion Pharmaceuticals; stock symbol to “HEPA”

Arbutus taking multi-faceted approach to HBV

William Blair analyst discusses Hep B space

General

More